Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals

US6303661A · kind A · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Hans-Ulrich Demuth · Halle (Saale), DE
• Fred Rosche · Schkopau, DE
• Joem Schmidt · Bodenwerder, DE
• Robert P. Pauly · Vancouver, CA
• Christopher McIntosh · Vancouver, CA
• Ray Pederson · Vancouver, CA

Key dates

• Filing date: Oct 6, 1998
• Grant date: Oct 16, 2001
• Expiry date: Oct 6, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.